LABHealthcare · Medical DevicesThe 1 Wall Street analysts covering Standard BioTools, Inc. hold a median 12-month price target of $1.35 — +101.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Standard BioTools, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (65): Sales and profits are climbing, and climbing faster than before.
Value (12): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LAB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +101.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Nov 2025 | TD Cowen | Maintains | Hold | $1.55 → $1.35 |
| 5 Nov 2025 | TD Cowen | Maintains | Hold | — |
| 27 Feb 2025 | Keybanc | Downgrade | Sector Weight | — |
| 31 Oct 2024 | TD Cowen | Maintains | Buy | — |
| 1 Aug 2024 | TD Cowen | Maintains | Buy | — |
| 16 Apr 2024 | TD Cowen | Initiates | Buy | — |
| 4 Apr 2024 | Jefferies | Initiates | Buy | — |
| 12 July 2023 | Keybanc | Initiates | Overweight | — |
| 27 Aug 2020 | UBS | Maintains | Buy | — |
| 10 Aug 2020 | UBS | Maintains | Buy | — |
| 6 Nov 2019 | Janney Montgomery Scott | Downgrade | Neutral | — |
| 18 Oct 2019 | UBS | Upgrade | Buy | — |
| 15 Mar 2019 | UBS | Initiates | Neutral | — |
| 14 Mar 2019 | BTIG | Initiates | Buy | — |
| 3 Jan 2019 | Janney Montgomery Scott | Upgrade | Buy | — |
| 2 Nov 2018 | Piper Sandler | Upgrade | Overweight | — |
| 5 Feb 2016 | Deutsche Bank | Maintains | Buy | — |
| 5 Feb 2016 | Mizuho | Upgrade | Buy | — |
| 20 Jan 2016 | Cowen & Co. | Downgrade | Market Perform | — |
| 6 Jan 2016 | Avondale Partners | Initiates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LAB appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Standard BioTools, Inc. returned −49.2% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 39% of US stocks
Cheaper than 84% of US stocks
Cheaper than 55% of US stocks
Higher than 18% of US stocks
Higher than 28% of US stocks
Higher than 65% of US stocks
Higher than 18% of US stocks
Higher than 99% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Standard BioTools, Inc. has a market value of $263.0M and an enterprise value of −$185.5M.
Revenue in the twelve months to 30 June 2026: $84.6M. The latest quarter shrank 7.6% year on year.
Net income over the same four quarters: $84.9M, a 100.4% net margin.
Diluted earnings per share, trailing twelve months: $0.22.
Free cash flow in the twelve months to 30 June 2026: −$82.6M.
Trailing P/E: −3.3×; forward P/E: −67.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Standard BioTools, Inc. employs 385 people — $220K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Standard BioTools, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Standard BioTools announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused exclusively on healthcare industries. The announcement was made on October 5, 2026.
Why it matters — LAB watchers would care because the divestiture could reshape the company's business portfolio and strategic focus.
Standard BioTools announced it has entered into a new purchase agreement with Element Biosystems, a subsidiary of GMT Venture, for the sale of its mass cytometry business. The company determined that GMT Venture's unsolicited acquisition proposal was superior, leading to the new agreement.
Why it matters — LAB watchers would care because the revised deal with a new buyer affects the terms and timing of the divestiture of the mass cytometry business.
Standard BioTools Inc. announced its financial results for the quarter ended June 30, 2026, in a press release dated August 5, 2026. The company disclosed the results for the second quarter of 2026.
Why it matters — LAB watchers rely on these quarterly results to gauge the company's recent financial performance and track its ongoing progress.
Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio, while Illumina will buy out contingent payments, both moves intended to advance Standard BioTools' merger with Treeline Biosciences.
Why it matters — LAB watchers would care because these transactions streamline the company's structure and remove financial contingencies that could affect the completion of the merger with Treeline Biosciences.
The 1 Wall Street analysts covering Standard BioTools, Inc. have a median 12-month price target of $1.35, with estimates ranging from $1.35 to $1.35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Standard BioTools, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Standard BioTools, Inc. 26 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Standard BioTools, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (65 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +101.4% from the last close, and Ticker Nerd's factor model ranks Standard BioTools, Inc. 26 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Standard BioTools, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.35 to $1.35 over the next 12 months.
Standard BioTools, Inc. returned -49.2% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Standard BioTools Inc. is a life sciences tools company that develops and commercializes precision genomic and proteomic solutions for biomedical research.
The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED". Standard BioTools announced it has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, an investment firm focused exclusively on healthcare industries. The announcement was made on October 5, 2026.
Standard BioTools Inc. is a life sciences tools company that develops and commercializes precision genomic and proteomic solutions for biomedical research. The company provides instrumentation, consumables, assays, software, and services used to study genes, proteins, cellular behavior, and tissue architecture across early discovery, translational, and clinical research workflows. Its product portfolio includes platforms for genomics, single-cell analysis, spatial biology, mass cytometry, and microfluidics, supporting applications in areas such as oncology, immunology, and biomarker discovery. Standard BioTools serves academic institutions, government laboratories, pharmaceutical companies, biotechnology firms, and clinical research organizations worldwide. The company focuses on helping researchers generate high-quality, reproducible biological data that can improve understanding of health and disease.
CEO Dr. Michael Egholm Ph.D. · 385 employees · United States · https://www.standardbio.com
